Literature DB >> 14720025

Adult respiratory distress syndrome: do selective anticoagulants help?

Steven Idell1.   

Abstract

The adult respiratory distress syndrome (ARDS) is a form of acute lung injury that is characterized by florid extravascular fibrin deposition. Thrombosis in the pulmonary vasculature and disseminated intravascular coagulation have also been observed in association with ARDS. Fibrin deposition does not occur in the normal lung but is virtually universal in acute lung injury induced by disparate insults. A large body of basic and preclinical evidence further implicates abnormalities of pathways of fibrin turnover in the pathogenesis of acute inflammation and fibrotic repair. Coagulation is locally upregulated in the injured lung, while fibrinolytic activity is depressed. These abnormalities occur concurrently and favor alveolar fibrin deposition. The systemic derangements of fibrin turnover in sepsis are similar to those that occur in the injured lung. Recent clinical trials demonstrate that interventions using selective anticoagulation can provide a mortality advantage and that selective anticoagulants differ in their ability to provide clinical benefit. Preclinical trials in primates with sepsis-induced ARDS now indicate that anticoagulant interventions that block the extrinsic coagulation pathway can protect against the development of pulmonary fibrin deposition as well as lung dysfunction and acute inflammation. These observations provide proof of principle that key steps in the coagulation cascade are appropriate therapeutic targets to prevent the development of acute lung injury in ARDS. Ongoing studies and prior publications also support the hypothesis that reversal of the fibrinolytic defect in ARDS could protect against the development of acute lung injury. In all, these studies suggest that fibrin deposition in the injured lung as well as abnormalities of coagulation and fibrinolysis are integral to the pathogenesis of ARDS. The ability of selective anticoagulants to effectively and safely alter clinical outcome in ARDS remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14720025     DOI: 10.1007/bf03257165

Source DB:  PubMed          Journal:  Am J Respir Med        ISSN: 1175-6365


  6 in total

1.  Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Yoshimasa Imoto; Atsushi Kato; Tetsuji Takabayashi; Whitney Stevens; James E Norton; Lydia A Suh; Roderick G Carter; Ava R Weibman; Kathryn E Hulse; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Bruce K Tan; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2019-09-25       Impact factor: 10.793

2.  The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells.

Authors:  Yee-Joo Tan; Puay-Yoke Tham; Daphne Z L Chan; Chih-Fong Chou; Shuo Shen; Burtram C Fielding; Timothy H P Tan; Seng Gee Lim; Wanjin Hong
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Short-chain fatty acids induce tissue plasminogen activator in airway epithelial cells via GPR41&43.

Authors:  Y Imoto; A Kato; T Takabayashi; M Sakashita; J E Norton; L A Suh; R G Carter; A R Weibman; K E Hulse; W Stevens; K E Harris; A T Peters; L C Grammer; B K Tan; K Welch; D B Conley; R C Kern; S Fujieda; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2018-03-24       Impact factor: 5.018

4.  Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Kathryn E Hulse; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Seong H Cho; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

Review 5.  Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions.

Authors:  Alexander V Ovechkin; David Lominadze; Kara C Sedoris; Tonya W Robinson; Suresh C Tyagi; Andrew M Roberts
Journal:  Arch Physiol Biochem       Date:  2007-02       Impact factor: 4.076

Review 6.  Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.

Authors:  Yee-Joo Tan; Seng Gee Lim; Wanjin Hong
Journal:  Antiviral Res       Date:  2006-06-06       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.